€19m placement stretches cell therapy player Cardio3
This article was originally published in Clinica
Belgian biotech company Cardio3 BioSciences has raised €19m ($24.66m) in a series D financing, with plans to raise a further €11m in the near future. But this is far less money than the company had planned, and it arrived far later. Furthermore, of the €19m, only €7m is new money: the rest - €12m – repays debt under existing convertible loans.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.